ETHealthworld.comRoche takes on Loxo, Bayer in gene-defined cancer classETHealthworld.comMUNICH: Roche's entrectinib cancer pill was shown to shrink tumours in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted ...Swiss stocks - Factors to watch on Oct. 22ReutersReuters Health News SummaryDevdiscourseReuters Science News SummaryNewslineall 20 news articles